Login / Signup

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.

Nirosen VijiaratnamChristine GirgesGrace AuldMarisa ChauKate MaclaganAlexa KingSimon S SkeneKashfia ChowdhurySteve HibbertHuw MorrisPatricia LimousinDilan AthaudaCamille B CarrollMichele T HuMonty SilverdaleGordon W DuncanRay ChaudhuriChristine LoSilvia Del DinAlison J YarnallLynn RochesterRachel GibsonJohn DicksonRachael HunterVincenzo LibriThomas Foltynie
Published in: BMJ open (2021)
NCT04232969, ISRCTN14552789.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • study protocol
  • phase iii
  • phase ii
  • randomized controlled trial
  • phase ii study
  • open label
  • squamous cell carcinoma
  • risk assessment
  • cross sectional